Black Diamond Therapeutics, Inc.
BDTX
$3.09
$0.0351.15%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.70% | -15.61% | -9.54% | -6.01% | 9.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.53% | -16.54% | -12.29% | -6.97% | 1.96% |
| Operating Income | 108.77% | 98.76% | 12.29% | 6.97% | -1.96% |
| Income Before Tax | 117.93% | 106.38% | 15.48% | 13.09% | 2.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 117.93% | 106.38% | 15.48% | 13.09% | 2.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.93% | 106.38% | 15.48% | 13.09% | 2.67% |
| EBIT | 108.77% | 98.76% | 12.29% | 6.97% | -1.96% |
| EBITDA | 109.20% | 99.16% | 12.24% | 6.86% | -2.11% |
| EPS Basic | 116.51% | 104.65% | 33.97% | 35.89% | 32.20% |
| Normalized Basic EPS | 118.18% | 106.39% | 35.50% | 36.00% | 32.39% |
| EPS Diluted | 115.08% | 103.60% | 33.97% | 35.89% | 32.20% |
| Normalized Diluted EPS | 117.07% | 105.39% | 35.50% | 36.00% | 32.39% |
| Average Basic Shares Outstanding | 8.13% | 17.83% | 25.34% | 34.16% | 43.78% |
| Average Diluted Shares Outstanding | 8.61% | 18.35% | 25.34% | 34.16% | 43.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |